Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Wyles, David; Ruane, Peter; Sulkowski, Mark; T. Dieterich, Douglas; F. Luetkemeyer, Anne; R. Morgan, Timothy; E. Sherman, Kenneth; Dretler, Robin; Fishbein, Dawn; Gathe, Joseph; Henn, Sarah; Hinestrosa, Federico; Huynh, Charles; McDonald, Cheryl; Mills, Anthony; T. Overton, Edgar; Ramgopal, Moti; Rashbaum, Bruce; Ray, Graham; Scarsella, Anthony; L Yozviak, Joseph; McPhee, Fiona; Liu, Zhaohui; Hughes, Eric; D. Yin, Philip; Noviello, Stephanie; Ackerman, Peter

doi:10.1056/nejmoa1503153

Public

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Published in New England Journal of Medicine • Jul 21, 2015

Authors:

David Wyles

Peter Ruane

Mark Sulkowski

Abstract

BACKGROUND: The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type...

Subject

Medicine

Daclatasvir

Sofosbuvir

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!